Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial

被引：0
|
作者：
Wang, J. [1 ]
Wu, T. [1 ]
Hong, Y-G. [1 ]
Luo, S-X. [2 ]
Li, N. [2 ]
Guo, Y-Z. [3 ]
Cheng, Y-F. [4 ]
机构：
[1] Anyang Tumour Hosp, Med Oncol Dept, Anyang, Peoples R China
[2] Henan Canc Hosp, Med Oncol Dept, Zhengzhou, Peoples R China
[3] Henan Univ Sci & Technol, Affiliated Hosp 1, Med Oncol Dept, Luoyang, Peoples R China
[4] Shandong Univ, Qilu Hosp, Med Oncol Dept, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1513
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1404P
引用
收藏
页码：S1058 / S1058
页数：1
相关论文
共 50 条
  • [41] Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial
    Jin, Shuiling
    Zhao, Ruihua
    Zhou, Chuang
    Zhong, Qian
    Shi, Jianxiang
    Su, Chang
    Li, Qinglong
    Su, Xiaoxing
    Chi, Huabin
    Lu, Xu
    Jiang, Guozhong
    Chen, Renyin
    Han, Jinming
    Jiang, Miao
    Qiao, Shishi
    Liu, Jingjing
    Song, Min
    Song, Lijie
    Du, Yabing
    Chang, Zhiwei
    Wang, Meng
    Dong, Meilian
    Zhong, Yali
    Yu, Pu
    Zhang, Xiaojian
    Zong, Hong
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (08) : 1648 - 1658
  • [42] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Kjetil Boye
    Alessandra Longhi
    Tormod Guren
    Susanne Lorenz
    Stine Næss
    Michela Pierini
    Ingeborg Taksdal
    Ingvild Lobmaier
    Marilena Cesari
    Anna Paioli
    Ayca M. Løndalen
    Elisabetta Setola
    Ivar Hompland
    Leonardo A. Meza-Zepeda
    Kirsten Sundby Hall
    Emanuela Palmerini
    Cancer Immunology, Immunotherapy, 2021, 70 : 2617 - 2624
  • [43] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Boye, Kjetil
    Longhi, Alessandra
    Guren, Tormod
    Lorenz, Susanne
    Naess, Stine
    Pierini, Michela
    Taksdal, Ingeborg
    Lobmaier, Ingvild
    Cesari, Marilena
    Paioli, Anna
    Londalen, Ayca M.
    Setola, Elisabetta
    Hompland, Ivar
    Meza-Zepeda, Leonardo A.
    Hall, Kirsten Sundby
    Palmerini, Emanuela
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (09) : 2617 - 2624
  • [44] Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006) a multicentre, open-label, single-arm, phase 2 trial
    Xu, Bushu
    Pan, Qiuzhong
    Pan, Hua
    Li, Haomiao
    Li, Xianan
    Chen, Jing
    Pang, Danmei
    Zhang, Baoqing
    Weng, Desheng
    Peng, Ruiqing
    Fang, Meiyu
    Zhang, Xing
    ECLINICALMEDICINE, 2023, 64
  • [45] Re: SUCCINCT: An Open-Label, Single-Arm, Non-Randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-Line Treatment for Patients with Advanced Urothelial Carcinoma Editorial Comment
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2015, 194 (06): : 1583 - 1584
  • [46] Toripalimab in Combination With Induction Chemotherapy and Subsequent Chemoradiation as First-Line Treatment in Patients With Advanced/Metastatic Esophageal Carcinoma: Protocol for a Single-Arm, Prospective, Open-Label, Phase II Clinical Trial (TR-EAT)
    Wu, Lei
    Wang, Yi
    Li, Baisen
    Wan, Gang
    Liang, Long
    Li, Tao
    Lang, Jinyi
    Wang, Qifeng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [47] Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial
    Zhao, Shuangshuang
    Zhang, Minmin
    Zhang, Qing
    Wu, Jingjun
    Dai, Hui
    BMC CANCER, 2024, 24 (01)
  • [48] Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial
    Shuangshuang Zhao
    Minmin Zhang
    Qing Zhang
    Jingjun Wu
    Hui Dai
    BMC Cancer, 24
  • [49] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
    Ali A. Mokdad
    Hao Zhu
    Muhammad S. Beg
    Yull Arriaga
    Jonathan E. Dowell
    Amit G. Singal
    Adam C. Yopp
    Targeted Oncology, 2019, 14 : 541 - 550
  • [50] Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
    Zhang, Changgong
    Chen, Jianhua
    Wu, Huijuan
    Wang, Jun
    Gao, Liying
    Zhao, Jun
    Sun, Yan
    Jia, Zhongyao
    Mu, Xinlin
    Bai, Chunmei
    Wang, Rui
    Wu, Kailiang
    Liu, Qiang
    Shi, Yuankai
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (04): : 268 - 275
12345